TrialDrugs in R&D2014

Switching α-glucosidase inhibitors to miglitol reduced glucose fluctuations and circulating cardiovascular disease risk factors in type 2 diabetic Japanese patients.

Natsuyo Hariya et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.